eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2022
vol. 39
 
Share:
Share:
Original paper

Role of Bcl-2, p53, and Ki-67 expression in basal cell carcinoma and their association with aggressive and non-aggressive histological phenotypes

Raúl Gerardo Mendez-Flores
1
,
Diana Emilia Martínez-Fernández
2
,
Diego Ernesto Vega-De la Torre
3
,
Marianela Zambrano-Román
2
,
José Francisco Muñoz-Valle
2
,
Mario Gaston Toledo-Lelevier
1
,
Elizabeth Guevara-Gutiérrez
4
,
Marisol Ramírez-Padilla
1
,
Emmanuel Valdés-Alvarado
2

  1. Department of Dermatology, Civil Hospital of Guadalajara “Fray Antonio Alcalde”, Guadalajara, Mexico
  2. Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico
  3. Department of Pathology, Civil Hospital of Guadalajara “Fray Antonio Alcalde”, Guadalajara, Mexico
  4. Department of Dermatology, Instituto Dermatológico de Jalisco “Dr. José Barba Rubio”, Secretaría de Salud Jalisco, Zapopan Jalisco, México
Adv Dermatol Allergol 2022; XXXIX (3): 517-523
Online publish date: 2022/07/14
Article file
- Role of bcl-2.pdf  [0.22 MB]
Get citation
 
 

Introduction

Basal cell carcinoma (BCC) has a slow growth rate, minimal soft tissue invasiveness, and a high cure rate. Occasionally, BCC can behave aggressively, invading deep tissues, and potentially having metastatic behaviour. Nodular and superficial BCC subtypes are classically acknowledged as non-aggressive or less aggressive BCCs (nBCC), while more aggressive BCCs (aBCC) include the following patterns: metatypical, micronodular and infiltrative or morpheaform [1].

The association between the prognosis of solid tumours and the p53, Ki-67, and Bcl-2 biomarker expression has not been fully elucidated. The tumour suppressor p53 is the most frequently mutated gene in human cancers, and its inactivation is the second most frequent event following upregulation of the Hedgehog signalling pathway in BCC [2]. Several studies on p53 expression in BCCs reported a significantly greater expression of p53 in the aggressive groups, stating that p53 immunoexpression is an important prognostic factor for these tumours [3].

Expression of the nuclear protein Ki-67 is associated with cell proliferation. It has been used as a marker of tumour aggressiveness in solid tumours and some haematological malignancies. The prognostic implications of Ki-67 have been examined in numerous well-established studies [4, 5].

A key regulator of the mitochondrial apoptotic pathway is Bcl-2, favouring cell survival by inhibiting adapters necessary for the activation and cleavage of caspases. It promotes cell viability without promoting cell proliferation [6].

Previous studies have described that Bcl-2 is highly expressed in several hematologic and solid malignancies. However, recent evidence suggests that Bcl-2 is an independent favourable prognostic marker in basal cell carcinoma, breast cancer, and non-small cell lung cancer [710].

Aim

This study aimed to investigate the clinicopathological features and immunohistochemical expressions of p53, Ki-67, and Bcl-2 in cutaneous basal cell carcinoma focusing on histological subtypes. Their roles and possible interactions in the development and progression of BCC are discussed.

Material and methods

Data and specimen selection

A cross-sectional study was carried out in the Dermatology Service of Civil Hospital of Guadalajara from June 2018 to June 2019, where a total of 50 BCCs from 50 patients from Western Mexico were analysed and grouped by histological subtype. Samples were excluded if there was insufficient material, over-fixed material, or artefact by the process. Clinical data including gender and age at diagnosis were recorded. This study was approved by the local ethics committee and the institutional review board.

Histopathologic examination

The histopathological subtypes were re-confirmed and in tumours with mixed histological subtypes, the predominant component was recorded. Additional variables such as desmoplasia, Clark level, solar elastosis and pigment deposition were also evaluated. The haematoxylin-eosin stained sections of all samples were reviewed by two experienced pathologists (D.E.V) to determine the histological subtype and then immunohistochemistry expression was graded.

Immunohistochemistry

Immunohistochemical staining of p53, Ki-67 and Bcl-2 was performed using automated staining with the Benchmark ULTRA system (Ventana Medical Systems, AZ, USA). For each BCC, a 4 µm thick section of paraffin was mounted on a Menzel SuperFrost Plus adhesive slide and the manufacturer’s specifications were followed using the Ventana Ultraview System. The antibodies used were the CONFIRM mouse monoclonal anti-Bcl-2 antibody 124 (Ventana), primary anti-p53 antibody Bp53-11 (Ventana) and CONFIRM rabbit anti-Ki-67 monoclonal primary antibody 30-9 (Ventana).

All slides included positive controls and the omission of the primary antibody was used as a negative control.

Expression grading

Cytoplasmic positivity for Bcl-2 and nuclear positivity for Ki-67 and p53 were evaluated. Only histological areas that presented the neoplasm were assessed. The staining intensity was classified from 0 to 3 (0 for negative staining, 1 for weak staining, 2 for moderate staining, and 3 for strong staining). Positivity was determined by observing all slides at low power (40×) and then randomly selecting three fields at high power (400×) to estimate an average percentage of immunolabelled positive cells. Disparities in percentages were solved by digital imaging analysis with QuPath software version 0.2.2 [10]. Percentage positivity was ranked from 0 to 4; 0 (no positive cells), 1 (< 10% of positive cells), 2 (10–50% of positive cells), 3 (51–80% of positive cells) and 4 (> 80% of positive cells). The sum of the ordinal scores for percentage and intensity of immunostaining allowed obtaining an expression score from 0 to 7, where 0–3 was considered as a low expression and 4–7 as a high expression.

Ethics

Institutional ethics committee registration number: 024/20. This study was performed in line with the principles of the Declaration of Helsinki.

Statistical analysis

The relationship between biomarker expression and the clinicopathological features were analysed using the Fisher’s exact test. Multinomial linear regression was conducted to recognize the association between the biomarkers ki-67, p53 and Bcl-2 and the rest of the variables. A correlation test was used to estimate the degree of association between variables. Statistical significance was considered with a value of p < 0.05. Data were analysed using IBM SPSS® statistics version 25 (Armonk, New York, USA).

Quality assessment

The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guidelines were used to evaluate manuscripts’ quality in order to enhance the possibilities of comparing results across studies involving molecular biomarkers [11].

Results

Clinico-pathological data

A total of 50 BCC samples from 50 patients were included, from June 2018 to June 2019. Clinicopathological results are shown in Table 1.

Table 1

Clinical and histological characteristics (n = 50)

VariableBCC n (%)
Age [years]67 ±15
Gender:
 Male20 (40)
 Female30 (60)
Histological subtype:
 Nodular25 (50)
 Morpheaform10 (18)
 Micronodular10 (18)
 Adenoid4 (8)
 Metatypical2 (4)
Solar elastosis:
 Present39 (78)
 Absent11 (22)
Pigment deposition:
 Present24 (48)
 Absent26 (52)
Clark level:
 V5 (10)
 IV27 (54)
 III17 (34)
 II1 (2)
 I0 (0)
Desmoplasia:
 Severe7 (14)
 Moderate26 (52)
 Mild15 (30)
 Absent2 (4)

Biomarker expression

High expression of p53 was found in 30 (60%) samples and low expression in 20 (40%) samples. High expression of ki-67 was found in 33 (66%) samples and low expression in 17 (34%) samples. High expression of Bcl-2 was found in 24 (48%) samples and low expression in 26 (52%) samples.

The immunohistochemical patterns evaluated as low (0–3) and high (4–7) expressions between non-aggressive BCCs and aggressive BCCs are shown in Figure 1. Representative immunohistochemical expressions are shown in Figure 2.

Figure 1

Immunohistochemical expression patterns in aggressive and non-aggressive (less aggressive) groups

/f/fulltexts/PDIA/47354/PDIA-39-47354-g001_min.jpg
Figure 2

Representative images of immunohistochemical expression of p53 (B, F, J, N), Ki-67 (C, G, K, O) and Bcl-2 (D, H, L, P) in infiltrative morpheaform basal cell carcinoma (A), nodular basal cell carcinoma (E), adenoid basal cell carcinoma (I) and infiltrative morpheaform basal cell carcinoma (M). A, E, G, I, J, M, N, O – 40×, B, C, D, F, K, L – 100×, H – 400×

/f/fulltexts/PDIA/47354/PDIA-39-47354-g002_min.jpg

Relationship and association of biomarker expression and clinicopathological variables

We observed a statistically significant association when BCCs were grouped as non-aggressive and aggressive subtypes for p53 (p = 0.04) and Bcl-2 (p < 0.01). No statistical association was found between Ki-67 and tumour aggressiveness. No statistical association was found between histological variables and biomarkers (Table 2).

Table 2

Relationship of immunostaining results for aggressive and non-aggressive groups of BCCs

BiomarkerExpressionTotalNon-aggressive BCCsAggressive BCCsP-value*
p53Low
High
20
30
15 (75)
14 (46.6)
5 (25)
16 (53.4)
0.04
Ki-67Low
High
17
33
10 (58.8)
19 (57.5)
7 (41.2)
14 (42.5)
0.93
Bcl-2Low
High
26
24
8 (30.7)
21 (87.5)
18 (69.3)
3 (12.5)
< 0.01

* P-value from the Fisher’s exact test.

Multinomial logistic regression analysis showed that the expression of Ki-67, p53 and Bcl-2 was statistically associated with the aggressiveness of the tumour. Compared with BCCs with low Bcl-2 expression, BCCs with high expression of Bcl-2 were obviously associated with a non-aggressive subtype (OR = 8.79; 95% CI: 3.21–61.9, p = 0.01). In addition, the odds ratio for associating a low expression of p53 (as compared to a high expression of p53) with a non-aggressive BCC was significant (OR = 6.4; 95% CI: 1.17–23.9, p = 0.006).

On the other hand, the probability of associating a high level of ki-67 (compared to a low level of ki-67) with a low aggressiveness was significant (OR = 2.96; 95% CI: 0.39–8.78, p = 0.05). Given that the latter value presents a borderline p-value, it should be taken with caution. There was no statistical significance with age, histological subtype, pigment deposition, desmoplasia or Clark level (Table 3).

Table 3

Multinomial logistic regression analysis

Low BCL-2aB Std. errorWaldP-valueOR (odds ratio)95% confidence interval for OR
Lower boundUpper bound
Low Ki-67Age–0.040.0272.200.130.960.911.01
Histological subtype–0.720.691.090.290.480.131.87
Sola elastosis1.441.141.60.214.20.4536.02
Pigment deposition–0.570.960.350.560.570.0863.73
Clark level–0.460.680.470.490.630.162.39
Desmoplasia0.610.570.650.421.840.428.16
Aggressive BCCs1.080.662.680.1012.930.8110.6
High Ki-67Age–0.0070.0220.110.740.990.951.04
Histological subtype0.290.510.330.571.340.493.65
Sola elastosis0.490.940.270.601.630.2610.39
Pigment deposition–0.250.870.0920.7620.770.144.23
Clark level0.120.570.050.831.130.373.49
Desmoplasia–0.250.5840.180.670.780.252.46
Aggressive BCCs1.080.553.80.052.960.398.78
Low p53Age–0.0260.0251.110.290.970.931.02
Histological subtype0.1450.5910.600.811.160.363.68
Sola elastosis1.081.041.090.292.940.3922.36
Pigment deposition–0.2050.950.0470.830.820.135.23
Clark level–0.430.660.430.510.650.182.35
Desmoplasia–0.0190.650.0010.970.980.2743.52
Aggressive BCCs1.860.677.60.0066.41.1723.9
High p53Age–0.0130.0220.3570.5500.980.941.03
Histological subtype–0.1010.520.0370.850.900.322.52
Sola elastosis0.440.990.190.661.550.2210.89
Pigment deposition–0.670.880.580.450.510.092.86
Clark level0.130.580.050.821.140.373.56
Desmoplasia0.1050.6160.0290.871.110.333.72
Aggressive BCCs0.630.561.260.261.880.625.69
High bcl2Age–0.030.0251.770.180.970.921.01
Histological subtype–0.070.590.0160.890.930.292.93
Sola elastosis1.431.021.980.164.190.5730.7
Pigment deposition–0.680.920.560.460.510.083.04
Clark level–0.2980.640.220.640.740.212.6
Desmoplasia0.1490.660.050.821.170.3214.48
Aggressive BCCs2.640.7612.30.018.793.2161.9

a The reference category. R2 = 0.244 (Cox and Snell).

Correlation between Bcl-2, p53, and Ki-67 expression and clinicopathological characteristics

A correlation test among biomarker expression and clinicopathological features was performed. Bcl-2 showed a significant negative correlation with age (correlation coefficient = –0.308, p ≤ 0.05) (Table 4).

Table 4

Correlation among biomarker expression and clinicopathological features

AgeKi-67 biomarkerp53 biomarkerBcl-2 biomarkerClark level
Age 0.1440.069–0.308*–0.088
Ki-67 biomarker 0.1440.103–0.071–0.032
p53 biomarker –0.0690.103–0.1140.137
BCL-2 biomarker –0.308*–0.071–0.114–0.231
Clark level –0.0880.1570.144–0.236

* P-value < 0.05.

Discussion

BCC histological subtypes considered aggressive are particularly more complicated to treat due to subclinical extension, local destruction, and unfavourable biologic behaviour with higher recurrence rates. In addition, histologic subtypes of BCC that include morpheaform, micronodular, and metatypical patterns, are more likely to metastasize [12, 13].

Increased nuclear staining for mutant p53 reflects a loss of function of p53. In sporadic BCCs, inactivating mutations in the TP53 gene have been found in 50% of BCCs [14]. Our analysis of p53 expression revealed a statistical association with tumour aggressiveness. These findings are consistent with Oana et al. [15] who found that infiltrative BCCs had higher p53 expression in comparison to the nodular subtype (p = 0.054). Likewise, Shamsimeymandi et al. [3] assessed p53 expression between aBCC and nBCC and found a significantly higher expression in the aggressive groups. In addition, Brito et al. [16] reported a higher expression in recurrent BCC and infiltrative BCC than the normal epidermis. Mutations of p53 may also have an impact on BCC treatment. A recent study of p53 expression found that cell lines that displayed mutations of p53 were more resistant to imiquimod-induced apoptosis [17]. Moreover, p53 expression was also associated with BCC resistance to photodynamic therapy (PDT) [18].

In our study, the number of tumour cells in BCC expressing Ki-67 antigen exhibited wide variation, and a high expression was found independent of the histological subtype. These findings are consistent with Shamsimeymandi et al. [3] who evaluated an equivalent number of cases amongst most histological subtypes (n = 22 aBCCs vs. 20 nBCCs) and found no difference in Ki-67 expression. However, Khalesi et al. [19] evaluated nBCC and found a significantly higher expression of Ki-67 in the superficial subtype compared to the nodular subtype. Interestingly, Yerebakan et al. [20] found strong differences (p < 0.0001) of expression in recurrent tumours but not between histological subtypes.

Our results concerning Bcl-2 are consistent with previous data, where nBCC had a higher expression. Like our study, all following studies found a significant difference between the two groups, with the expression being the highest in nBCCs and lowest in aBCCs. Ramdial et al. [21] reported a low Bcl-2 expression in all of their aBCCs compared to nBCCs (p < 0.02). Zagrodnik et al. [22] examined recurrent tumours in patients treated with radiotherapy and found a significant correlation between low Bcl-2 expression and aBCCs (p = 0.0169) but not with recurrences. Sivrikoz et al. [9] included more samples of aBCCs (n = 77) than nBCC (n = 23). The contrast of Bcl-2 expression in aBCC and nBCC in our study suggests that they form a complex group of tumours that differ considerably in morphologic and biological behaviour, despite the common origin of these tumours from basal stem cells [23]. In the context of these previous studies, our findings suggest that a high expression of Bcl-2 might be a favourable prognosis factor. This can be explained by the finding that although Bcl-2 inhibits apoptosis it may also slow cell growth [24]. It is known that ultraviolet (UV) radiation induces downregulation of Bcl-2 in vivo and in vitro [25]. A recent study concluded that apoptosis in BCC does not involve BAX and that the apoptotic activity of BCCs is regulated by either less common members of the BCL2 gene family or a BCL2 gene family independent pathway [26]. The increase in genetic mutations induced by UV or other carcinogens together with a spontaneous or UV-induced downregulation of Bcl-2 may result in aggressive biological behaviour in BCCs. UV chronic exposure could explain our findings of the correlation between older age and lower Bcl-2 expression.

Conclusions

We have found that a high expression of Bcl-2 and a low p53 expression is associated with more indolent histopathological features with better outcomes. Our results suggest that analysis of p53 and Bcl-2 expression in BCC patients may provide useful prognostic information. However, the clinical implications of these interactions in BCC need to be critically evaluated.

Acknowledgments

Carlos Slim Foundation Health Scholarship for research, Mexico City. This foundation was not involved in study design, collection, analysis, or interpretation of data.

Conflict of interest

The authors declare no conflict of interest.

References

1 

Walling HW, Fosko SW, Geraminejad PA, et al. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev 2004; 23: 389-402.

2 

Pellegrini C, Maturo MG, Di Nardo L, et al. Understanding the molecular genetics of basal cell carcinoma. Int J Mol Sci 2017; 18: 2485.

3 

ShamsiMeymandi S, Dabiri S, ZeynadiniMeymand A, et al. Evaluation of immunohistochemical findings and clinical features associated with local aggressiveness in basal cell carcinoma. Iran J Pathol 2019; 14: 193-6.

4 

Luo Y, Ren F, Liu Y, et al. Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis. Int J Clin Exp Med 2015; 8: 10235-47.

5 

Richards-Taylor S, Ewings SM, Jaynes E, et al. The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis. J Clin Pathol 2016; 69: 612-8.

6 

Ramdial PK, Madaree A, Reddy R, et al. Bcl-2 protein expression in aggressive and non-aggressive basal cell carcinomas. J Cutan Pathol 2000; 27: 283-91.

7 

Martinez-Arribas F, Alvarez T, Del Val G, et al. Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level. Anticancer Res 2007; 27: 219-22.

8 

Feng C, Wu J, Yang F, et al. Expression of Bcl-2 is a favorable prognostic biomarker in lung squamous cell carcinoma. Oncol Lett 2018; 15: 6925-30.

9 

Sivrikoz ON, Kandiloğlu G. The effects of cyclin D1 and Bcl-2 expression on aggressive behavior in basal cell and basosquamous carcinoma. Iran J Pathol 2015; 10: 185-91.

10 

Bankhead P, Loughrey MB, Fernández JA, et al. QuPath: open source software for digital pathology image analysis. Sci Rep 2017; 7: 16878.

11 

McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93: 387-91.

12 

Shih S, Dai C, Ansari A, et al. Metatypical basal cell carcinoma with intravascular invasion. Cureus 2018; 10: e3401.

13 

Gąsiorowski K, Iwulska K, Zapała J, et al. Periocular basal cell carcinoma: recurrence risk factors/when to reoperate? Adv Dermatol Allergol 2020; 37: 927-31.

14 

Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med 2015; 88: 167-79.

15 

Oana A, Stepan AE, Margaritescu C, et al. Immunoexpression of p53 and COX-2 in basal cell carcinoma. Rom J Morphol Embryol 2019; 59: 1115-20.

16 

Lima JSB, Miola AC, Marques MEA, et al. Patterns of proliferation and apoptosis in different subtypes of basal cell carcinoma, adjacent epidermis, and recurrent forms. An Bras Dermatol 2019; 94: 108-10.

17 

Huang SW, Chang SH, Mu SW, et al. Imiquimod activates p53-dependent apoptosis in a human basal cell carcinoma cell line. J Dermatol Sci 2016; 81: 182-91.

18 

Lucena SR, Zamarrón A, Carrasco E, et al. Characterisation of resistance mechanisms developed by basal cell carcinoma cells in response to repeated cycles of photodynamic therapy. Sci Rep 2019; 9: 4835.

19 

Khalesi M, Waterhouse M, Whiteman DC, et al. Comparison of PTCH1, COX-2, P53 and Ki-67 protein expression in basal cell carcinomas of nodular and superficial subtypes arising on the head and trunk. Int J Dermatol 2016; 55: 1096-105.

20 

Yerebakan O, Ciftçioglu MA, Akkaya BK, et al. Prognostic value of Ki-67, CD31 and epidermal growth factor receptor expression in basal cell carcinoma. J Dermatol 2003; 30: 33-41.

21 

Ramdial PK, Madaree A, Reddy R, et al. Bcl-2 protein expression in aggressive and non-aggressive basal cell carcinomas. J Cutan Pathol 2000; 27: 283-91.

22 

Zagrodnik B, Kempf W, Seifert B, et al. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. Cancer 2003; 98: 2708-14.

23 

Mansouri H, Mnango LF, Magorosa H, et al. Ki-67, p53 and BCL-2 Expressions and their association with clinical histopathology of breast cancer among women in Tanzania. Sci Rep 2019; 9: 9918.

24 

Pietenpol JA, Papadopoulos N, Markowitz S, et al. Paradoxical inhibition of solid tumor growth by Bcl-2. Cancer Res 1994; 54: 3714-7.

25 

Isoherranen K, Sauroja I, Jansen C, et al. UV irradiation induces downregulation of Bcl-2 expression in vitro and in vivo. Arch Dermatol Res 1999; 291: 212-6.

26 

Cho S, Hahm JH, Hong YS. Analysis of p53 and BAX mutations, loss of heterozygosity, p53 and BCL2 expression and apoptosis in basal cell carcinoma in Korean patients. Br J Dermatol 2001; 144: 841-8.

Copyright: © 2022 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.